Welcome to the Janssen Immunology UEGW 2020 Newsroom! Please see below for the latest meeting news, a message from our leaders, social feeds, and more information about our progress and commitment to developing innovative medicines for Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis.
Janssen’s Commitment to Inflammatory Bowel Disease
A Message from our Gastroenterology Leaders
We are honored to be sharing our latest research in inflammatory bowel disease at this year’s virtual United European Gastroenterology Week (UEGW). At Janssen, we remain steadfast in our commitment in IBD by seeking out solutions, uncovering novel treatment approaches, and working collaboratively with the brightest and most passionate minds to deliver transformational therapies for IBD patients. We recognize there is still much work to be done in IBD, and that many patients around the world are struggling to find the right treatment, maintain symptom relief and achieve remission. These unmet needs are what motivates and drives us to continue to pioneer in the area of IBD, so that people around the world can live free from disease.
Learn more about our research at UEGW below!
About Inflammatory Bowel Disease
IBD is an umbrella term used to describe disorders that cause chronic inflammation of the gastrointestinal (GI) tract. The two most common forms of IBD are Crohn’s disease and ulcerative colitis.1 IBD affects an estimated 3 million Americans and 1.7 million people across Europe.2,3
2 Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet 2017;390:2769-78. Accessed September 14, 2020.
3 Crohn's and Colitis Foundation. Overview of Crohn's Disease. Available at: https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview. Accessed September 14, 2020.